<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	>

<channel>
	<title>PharmaCompanies.info</title>
	<atom:link href="http://www.farmanux.com/wpnews/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.farmanux.com/wpnews</link>
	<description>Pharmaceutical Resources &#38; Pharma Top Blogs News</description>
	<pubDate>Fri, 03 Jul 2009 10:00:00 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.7.1</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>WHO, Wyeth Launch Trial In Africa To Test New River Blindness Drug</title>
		<link>http://www.farmanux.com/wpnews/2009/07/who-wyeth-launch-trial-in-africa-to-test-new-river-blindness-drug/</link>
		<comments>http://www.farmanux.com/wpnews/2009/07/who-wyeth-launch-trial-in-africa-to-test-new-river-blindness-drug/#comments</comments>
		<pubDate>Fri, 03 Jul 2009 10:00:00 +0000</pubDate>
		<dc:creator>Pharma Industry / Biotech Industry News From Medical News Today</dc:creator>
		
		<category><![CDATA[TopPharmaBlogs]]></category>

		<category><![CDATA[Tropical Diseases]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[IMS]]></category>

		<category><![CDATA[industry]]></category>

		<category><![CDATA[labs]]></category>

		<category><![CDATA[Market]]></category>

		<category><![CDATA[pharmaceutical]]></category>

		<category><![CDATA[pharmaceuticals]]></category>

		<category><![CDATA[pharmacy]]></category>

		<category><![CDATA[portfolio]]></category>

		<category><![CDATA[product]]></category>

		<guid isPermaLink="false">http://www.medicalnewstoday.com/articles/156297.php</guid>
		<description><![CDATA[The WHO on Wednesday announced plans for a clinical trial to test a new drug that "could halve the treatment period for river blindness [or onchocerciasis], a disease that threatens 100 million people mostly in Africa," AFP/Dow Jones Newswires/CNN Money reports (7/1).]]></description>
		<wfw:commentRss>http://www.farmanux.com/wpnews/2009/07/who-wyeth-launch-trial-in-africa-to-test-new-river-blindness-drug/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Current Status Of The Development Programs Of New Indications And Formulations For Aricept(R) For Enhancing Patient Value</title>
		<link>http://www.farmanux.com/wpnews/2009/07/current-status-of-the-development-programs-of-new-indications-and-formulations-for-ariceptr-for-enhancing-patient-value/</link>
		<comments>http://www.farmanux.com/wpnews/2009/07/current-status-of-the-development-programs-of-new-indications-and-formulations-for-ariceptr-for-enhancing-patient-value/#comments</comments>
		<pubDate>Fri, 03 Jul 2009 09:00:00 +0000</pubDate>
		<dc:creator>Pharma Industry / Biotech Industry News From Medical News Today</dc:creator>
		
		<category><![CDATA[Alzheimer's / Dementia]]></category>

		<category><![CDATA[TopPharmaBlogs]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[IMS]]></category>

		<category><![CDATA[industry]]></category>

		<category><![CDATA[labs]]></category>

		<category><![CDATA[Market]]></category>

		<category><![CDATA[pharmaceutical]]></category>

		<category><![CDATA[pharmaceuticals]]></category>

		<category><![CDATA[pharmacy]]></category>

		<category><![CDATA[portfolio]]></category>

		<category><![CDATA[product]]></category>

		<guid isPermaLink="false">http://www.medicalnewstoday.com/articles/156271.php</guid>
		<description><![CDATA[Eisai Co., Ltd. (Headquarters: Tokyo, President &#38; CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical development programs for the company's major product Aricept(R) (donepezil hydrochloride tablets) to further contribute to patients with Alzheimer's disease. As progress in those programs has been made, Eisai announces the status as follows:    1.]]></description>
		<wfw:commentRss>http://www.farmanux.com/wpnews/2009/07/current-status-of-the-development-programs-of-new-indications-and-formulations-for-ariceptr-for-enhancing-patient-value/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Spanish Government Selects Novavax&#8217;s VLP Technology For Comprehensive Flu Vaccine Solution In Spain</title>
		<link>http://www.farmanux.com/wpnews/2009/07/spanish-government-selects-novavaxs-vlp-technology-for-comprehensive-flu-vaccine-solution-in-spain/</link>
		<comments>http://www.farmanux.com/wpnews/2009/07/spanish-government-selects-novavaxs-vlp-technology-for-comprehensive-flu-vaccine-solution-in-spain/#comments</comments>
		<pubDate>Fri, 03 Jul 2009 09:00:00 +0000</pubDate>
		<dc:creator>Pharma Industry / Biotech Industry News From Medical News Today</dc:creator>
		
		<category><![CDATA[Flu / Cold / SARS]]></category>

		<category><![CDATA[TopPharmaBlogs]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[IMS]]></category>

		<category><![CDATA[industry]]></category>

		<category><![CDATA[labs]]></category>

		<category><![CDATA[Market]]></category>

		<category><![CDATA[pharmaceutical]]></category>

		<category><![CDATA[pharmaceuticals]]></category>

		<category><![CDATA[pharmacy]]></category>

		<category><![CDATA[portfolio]]></category>

		<category><![CDATA[product]]></category>

		<guid isPermaLink="false">http://www.medicalnewstoday.com/articles/156267.php</guid>
		<description><![CDATA[Novavax, Inc. (Nasdaq:  NVAX) announced its initial agreement to license its proprietary, recombinant virus-like-particle (VLP) vaccine technology to ROVI Pharmaceuticals (Madrid: ROVI) of Spain.]]></description>
		<wfw:commentRss>http://www.farmanux.com/wpnews/2009/07/spanish-government-selects-novavaxs-vlp-technology-for-comprehensive-flu-vaccine-solution-in-spain/feed/</wfw:commentRss>
		</item>
		<item>
		<title>FDA Approves Multaq(R) For Patients With Atrial Fibrillation Or Atrial Flutter</title>
		<link>http://www.farmanux.com/wpnews/2009/07/fda-approves-multaqr-for-patients-with-atrial-fibrillation-or-atrial-flutter/</link>
		<comments>http://www.farmanux.com/wpnews/2009/07/fda-approves-multaqr-for-patients-with-atrial-fibrillation-or-atrial-flutter/#comments</comments>
		<pubDate>Fri, 03 Jul 2009 09:00:00 +0000</pubDate>
		<dc:creator>Pharma Industry / Biotech Industry News From Medical News Today</dc:creator>
		
		<category><![CDATA[Cardiovascular / Cardiology]]></category>

		<category><![CDATA[TopPharmaBlogs]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[IMS]]></category>

		<category><![CDATA[industry]]></category>

		<category><![CDATA[labs]]></category>

		<category><![CDATA[Market]]></category>

		<category><![CDATA[pharmaceutical]]></category>

		<category><![CDATA[pharmaceuticals]]></category>

		<category><![CDATA[pharmacy]]></category>

		<category><![CDATA[portfolio]]></category>

		<category><![CDATA[product]]></category>

		<guid isPermaLink="false">http://www.medicalnewstoday.com/articles/156266.php</guid>
		<description><![CDATA[Sanofi-aventis (EURONEXT: SAN and NYSE:  SNY) announced that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq(R) is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.]]></description>
		<wfw:commentRss>http://www.farmanux.com/wpnews/2009/07/fda-approves-multaqr-for-patients-with-atrial-fibrillation-or-atrial-flutter/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Acura And King Receive FDA Complete Response Letter Regarding Acurox(R)</title>
		<link>http://www.farmanux.com/wpnews/2009/07/acura-and-king-receive-fda-complete-response-letter-regarding-acuroxr/</link>
		<comments>http://www.farmanux.com/wpnews/2009/07/acura-and-king-receive-fda-complete-response-letter-regarding-acuroxr/#comments</comments>
		<pubDate>Fri, 03 Jul 2009 08:00:00 +0000</pubDate>
		<dc:creator>Pharma Industry / Biotech Industry News From Medical News Today</dc:creator>
		
		<category><![CDATA[Pain / Anesthetics]]></category>

		<category><![CDATA[TopPharmaBlogs]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[IMS]]></category>

		<category><![CDATA[industry]]></category>

		<category><![CDATA[labs]]></category>

		<category><![CDATA[Market]]></category>

		<category><![CDATA[pharmaceutical]]></category>

		<category><![CDATA[pharmaceuticals]]></category>

		<category><![CDATA[pharmacy]]></category>

		<category><![CDATA[portfolio]]></category>

		<category><![CDATA[product]]></category>

		<guid isPermaLink="false">http://www.medicalnewstoday.com/articles/156265.php</guid>
		<description><![CDATA[Acura Pharmaceuticals, Inc. (Nasdaq:  ACUR) and King Pharmaceuticals, Inc. (NYSE:  KG) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding the New Drug Application (NDA) for Acurox (oxycodone HC1, USP and niacin, USP) Tablets CII, an immediate release product intended for the relief of moderate-to-severe pain.         The Complete Response Letter raises issues regarding the potential abuse deterrent benefits of Acurox(R).]]></description>
		<wfw:commentRss>http://www.farmanux.com/wpnews/2009/07/acura-and-king-receive-fda-complete-response-letter-regarding-acuroxr/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Lixte Biotechnology Holdings&#8217; Lead Compound, LB-1.2, Enhances The Effectiveness Of Standard Cancer Chemotherapy In Animal Models</title>
		<link>http://www.farmanux.com/wpnews/2009/07/lixte-biotechnology-holdings-lead-compound-lb-12-enhances-the-effectiveness-of-standard-cancer-chemotherapy-in-animal-models/</link>
		<comments>http://www.farmanux.com/wpnews/2009/07/lixte-biotechnology-holdings-lead-compound-lb-12-enhances-the-effectiveness-of-standard-cancer-chemotherapy-in-animal-models/#comments</comments>
		<pubDate>Fri, 03 Jul 2009 08:00:00 +0000</pubDate>
		<dc:creator>Pharma Industry / Biotech Industry News From Medical News Today</dc:creator>
		
		<category><![CDATA[Cancer / Oncology]]></category>

		<category><![CDATA[TopPharmaBlogs]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[IMS]]></category>

		<category><![CDATA[industry]]></category>

		<category><![CDATA[labs]]></category>

		<category><![CDATA[Market]]></category>

		<category><![CDATA[pharmaceutical]]></category>

		<category><![CDATA[pharmaceuticals]]></category>

		<category><![CDATA[pharmacy]]></category>

		<category><![CDATA[portfolio]]></category>

		<category><![CDATA[product]]></category>

		<guid isPermaLink="false">http://www.medicalnewstoday.com/articles/156264.php</guid>
		<description><![CDATA[Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced that investigators of the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), National Institutes of Health and Lixte reported that its novel compound, LB-1.2, enhances the effectiveness of two standard chemotherapy drugs in mouse models of human cancers. This research is being conducted under a Cooperative Research and Development Agreement between NINDS and Lixte.]]></description>
		<wfw:commentRss>http://www.farmanux.com/wpnews/2009/07/lixte-biotechnology-holdings-lead-compound-lb-12-enhances-the-effectiveness-of-standard-cancer-chemotherapy-in-animal-models/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Drug Industry Increases Lobbying Efforts And Targets Democrats</title>
		<link>http://www.farmanux.com/wpnews/2009/07/drug-industry-increases-lobbying-efforts-and-targets-democrats/</link>
		<comments>http://www.farmanux.com/wpnews/2009/07/drug-industry-increases-lobbying-efforts-and-targets-democrats/#comments</comments>
		<pubDate>Thu, 02 Jul 2009 11:00:00 +0000</pubDate>
		<dc:creator>Pharma Industry / Biotech Industry News From Medical News Today</dc:creator>
		
		<category><![CDATA[Pharma Industry / Biotech Industry]]></category>

		<category><![CDATA[TopPharmaBlogs]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[IMS]]></category>

		<category><![CDATA[industry]]></category>

		<category><![CDATA[labs]]></category>

		<category><![CDATA[Market]]></category>

		<category><![CDATA[pharmaceutical]]></category>

		<category><![CDATA[pharmaceuticals]]></category>

		<category><![CDATA[pharmacy]]></category>

		<category><![CDATA[portfolio]]></category>

		<category><![CDATA[product]]></category>

		<guid isPermaLink="false">http://www.medicalnewstoday.com/articles/156158.php</guid>
		<description><![CDATA[The drug industry began ramping up its lobbying efforts in 2003, when Medicare Part D began, and now is targeting Democrats.                 CQ Politics reports: "The industry is increasingly employing Democratic lobbyists with ties to the Obama administration and congressional leaders such as Sen. Max Baucus, D-Mont., chairman of the Senate Finance Committee.]]></description>
		<wfw:commentRss>http://www.farmanux.com/wpnews/2009/07/drug-industry-increases-lobbying-efforts-and-targets-democrats/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Questions Linger Over Pharmaceutical Deal Agreement To Cut Costs</title>
		<link>http://www.farmanux.com/wpnews/2009/07/questions-linger-over-pharmaceutical-deal-agreement-to-cut-costs/</link>
		<comments>http://www.farmanux.com/wpnews/2009/07/questions-linger-over-pharmaceutical-deal-agreement-to-cut-costs/#comments</comments>
		<pubDate>Thu, 02 Jul 2009 11:00:00 +0000</pubDate>
		<dc:creator>Pharma Industry / Biotech Industry News From Medical News Today</dc:creator>
		
		<category><![CDATA[Health Insurance / Medical Insurance]]></category>

		<category><![CDATA[TopPharmaBlogs]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[IMS]]></category>

		<category><![CDATA[industry]]></category>

		<category><![CDATA[labs]]></category>

		<category><![CDATA[Market]]></category>

		<category><![CDATA[pharmaceutical]]></category>

		<category><![CDATA[pharmaceuticals]]></category>

		<category><![CDATA[pharmacy]]></category>

		<category><![CDATA[portfolio]]></category>

		<category><![CDATA[product]]></category>

		<guid isPermaLink="false">http://www.medicalnewstoday.com/articles/156152.php</guid>
		<description><![CDATA[ "As details emerge of the pharmaceutical industry's agreement to kick in $80 billion to help pay for health care reform, the deal is facing increasing skepticism from inside and outside the health care industry," Politico reports.]]></description>
		<wfw:commentRss>http://www.farmanux.com/wpnews/2009/07/questions-linger-over-pharmaceutical-deal-agreement-to-cut-costs/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Roche To Offer Developing Countries Discounted Tamiflu</title>
		<link>http://www.farmanux.com/wpnews/2009/07/roche-to-offer-developing-countries-discounted-tamiflu/</link>
		<comments>http://www.farmanux.com/wpnews/2009/07/roche-to-offer-developing-countries-discounted-tamiflu/#comments</comments>
		<pubDate>Thu, 02 Jul 2009 10:00:00 +0000</pubDate>
		<dc:creator>Pharma Industry / Biotech Industry News From Medical News Today</dc:creator>
		
		<category><![CDATA[Swine Flu]]></category>

		<category><![CDATA[TopPharmaBlogs]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[IMS]]></category>

		<category><![CDATA[industry]]></category>

		<category><![CDATA[labs]]></category>

		<category><![CDATA[Market]]></category>

		<category><![CDATA[pharmaceutical]]></category>

		<category><![CDATA[pharmaceuticals]]></category>

		<category><![CDATA[pharmacy]]></category>

		<category><![CDATA[portfolio]]></category>

		<category><![CDATA[product]]></category>

		<guid isPermaLink="false">http://www.medicalnewstoday.com/articles/156138.php</guid>
		<description><![CDATA[The pharmaceutical company Roche on Wednesday announced a program to help ensure developing countries have access to its antiviral Tamiflu, for "the management of a novel influenza strain defined by the WHO as having significant and current pandemic potential," Reuters reports (Egenter, 7/1).]]></description>
		<wfw:commentRss>http://www.farmanux.com/wpnews/2009/07/roche-to-offer-developing-countries-discounted-tamiflu/feed/</wfw:commentRss>
		</item>
		<item>
		<title>Potential New Drugs: 970 Million And Still Counting - Journal Of The American Chemical Society</title>
		<link>http://www.farmanux.com/wpnews/2009/07/potential-new-drugs-970-million-and-still-counting-journal-of-the-american-chemical-society/</link>
		<comments>http://www.farmanux.com/wpnews/2009/07/potential-new-drugs-970-million-and-still-counting-journal-of-the-american-chemical-society/#comments</comments>
		<pubDate>Thu, 02 Jul 2009 10:00:00 +0000</pubDate>
		<dc:creator>Pharma Industry / Biotech Industry News From Medical News Today</dc:creator>
		
		<category><![CDATA[Pharma Industry / Biotech Industry]]></category>

		<category><![CDATA[TopPharmaBlogs]]></category>

		<category><![CDATA[biotech]]></category>

		<category><![CDATA[IMS]]></category>

		<category><![CDATA[industry]]></category>

		<category><![CDATA[labs]]></category>

		<category><![CDATA[Market]]></category>

		<category><![CDATA[pharmaceutical]]></category>

		<category><![CDATA[pharmaceuticals]]></category>

		<category><![CDATA[pharmacy]]></category>

		<category><![CDATA[portfolio]]></category>

		<category><![CDATA[product]]></category>

		<guid isPermaLink="false">http://www.medicalnewstoday.com/articles/156116.php</guid>
		<description><![CDATA[Like astronomers counting stars in the familiar universe of outer space, chemists in Switzerland are reporting the latest results of a survey of chemical space - the so-called chemical universe where tomorrow's miracle drugs may reside. The scientists conclude, based on this phase of the ongoing count, that there are 970 million chemicals suitable for study as new drugs.]]></description>
		<wfw:commentRss>http://www.farmanux.com/wpnews/2009/07/potential-new-drugs-970-million-and-still-counting-journal-of-the-american-chemical-society/feed/</wfw:commentRss>
		</item>
	</channel>
</rss>
